Table 2.
Baseline characteristics of COVID-19 patients based on the mortality status (N=362)
| Characteristics | Total N=362 | Survivor N=280 (77.3%) | Non-Survivor N=82 (22.7%) | P-Value |
|---|---|---|---|---|
| Age, median (IQR) | 55 (22) | 51 (23) | 63 (19) | <0.001 |
| Gender, n (%) | ||||
| Male | 205 (56.6%) | 155 (55.4%) | 50 (61.0%) | 0.367 |
| Female | 157 (43.4%) | 125 (44.6%) | 32 (39.0%) | |
| Comorbidity, n (%) | ||||
| Hypertension | 121 (33.5%) | 96 (34.4%) | 25 (30.5%) | 0.508 |
| Diabetes | 102 (28.2%) | 78 (27.9%) | 24 (29.3%) | 0.803 |
| IHD | 16 (4.4%) | 14 (5.0%) | 2 (2.4%) | 0.540 |
| Other | (< 4.0%) | |||
| Common symptoms, n (%) | ||||
| SOB | 81 (22.4%) | 74 (26.4%) | 7 (8.5%) | <0.001 |
| Dry cough | 58 (16.0%) | 55 (16.6%) | 3 (3.7%) | <0.001 |
| Fever | 44 (12.2%) | 40 (14.3%) | 4 (4.9%) | 0.022 |
| Chest pain | 31 (8.6%) | 30 (10.7%) | 1 (1.2%) | 0.007 |
| Headache | 25 (6.9%) | 23 (8.2%) | 2 (2.4%) | 0.070 |
| Vomiting | 23 (6.4%) | 19 (6.8%) | 4 (4.9%) | 0.533 |
| Sore throat | 22 (6.1%) | 21 (7.6%) | 1 (1.2%) | 0.035 |
| Productive cough | 21 (5.8%) | 20 (7.2%) | 1 (1.2%) | 0.056 |
| Diarrhea | 21 (5.8%) | 19 (6.8%) | 2 (2.4%) | 0.183 |
| General fatigue | 20 (5.5%) | 18 (6.4%) | 2 (2.4%) | 0.269 |
| Abdominal pain | 15 (5.3%) | 18 (6.5%) | 1 (1.2%) | 0.088 |
| Loss of taste and smell | 18 (5.0%) | 17 (6.1%) | 1 (1.2%) | 0.087 |
| Others | (< 5.0%) | |||
| Treatment, n (%) | ||||
| Antibiotics | 239 (66.0%) | 205 (73.2%) | 34 (41.5%) | <0.001 |
| Vitamins | 206 (56.9%) | 192 (68.6%) | 14 (17.1%) | <0.001 |
| Anticoagulant | 194 (53.6%) | 163 (58.2%) | 31 (37.8%) | 0.001 |
| Corticosteroids | 174 (48.1%) | 144 (51.4%) | 30 (36.6%) | 0.018 |
| Oxygen therapy | 144 (39.8%) | 124 (44.3%) | 20 (24.4%) | 0.001 |
| Antiplatelet | 78 (21.5%) | 63 (22.5%) | 15 (18.3%) | 0.415 |
| Antiviral | 34 (9.4%) | 29 (10.4%) | 5 (6.5%) | 0.245 |
| mAb (tocilizumab) | 24 (6.6%) | 15 (5.4%) | 9 (11.0%) | 0.072 |
| Length of stay, median (IQR) | 11 (12) days | 10 (12) days | 13 (11) days | 0.282 |